Immatics N.V. share price logo

Immatics N.V.

NASDAQ: IMTX

Small Cap

$9.78

+0.26

(+2.73%)

as on

Immatics N.V. Stock Performance

as on June 19, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $9.62
    $9.98
    downward going graph

    1.64%

    Downside

    2.04%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $5.05
    $12.41
    downward going graph

    48.36%

    Downside

    26.89%

    Upside

    downward going graph

Immatics N.V. share price movements today

Previous Close
$9.52
Open
$9.81
Volume
467.9K
Day's Low - High
$9.62 - $9.98
52 Week Low - High
$5.05 - $12.41

Immatics N.V. Historical Returns

1 Month Return
-8.6 %
3 Month Return
+ 0.72 %
1 Year Return
+ 67.18 %
3 Year Return
-23.11 %
5 Year Return
-17.12 %

Immatics N.V. Stock Fundamentals & Key Indicators

Check Immatics N.V. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.3B

EPS (TTM)

-1.9456

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-203.9M

Revenue (TTM)

37.3M

Profit Margin

0.00%

Return On Equity TTM

-43.21%

Immatics N.V. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Immatics N.V. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Immatics N.V. image
Immatics N.V.
BUY$1.3B-17.12%NA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$37.7B57.21%71.2112.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$116.5B140.42%27.2235.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$63.7B13.39%14.8529.65%0.58%

Stock Returns calculator for Immatics N.V. Stock including INR - Dollar returns

The Immatics N.V. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Immatics N.V. investment value today

Current value as on today

₹1,81,559

Returns

₹81,559

(+81.56%)

Returns from Immatics N.V. Stock

₹67,179 (+67.18%)

Dollar Impact

₹14,380 (+14.38%)

Analyst Recommendation on Immatics N.V. Stock

Based on 14 analysts

BUY

92.86%

Buy

7.14%

Hold

0.00%

Sell

Based on 14 analysts, 92.86% of analysts recommend a 'BUY' rating for Immatics N.V.. Average target price of $18.77

Immatics N.V. Share Price Target

Get share price movements and forecasts by analysts on Immatics N.V..

What analysts predicted

47.9%UPSIDE

Target Price

$18.77

Current Price

$9.78

Analyzed by

14 Analysts

Target

$18.77

Immatics N.V. target price $18.77, a slight upside of 47.9% compared to current price of $9.78. According to 14 analysts rating.

Indian Investors' Interest in Immatics N.V. Stock

Search interest for Immatics N.V. Stock has decreased by -10% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-10% versus previous 30 day period

Immatics N.V. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
17
33
20
56
58
20
4
5
19
7
Gross Profit
-18
-1
20
56
58
20
4
5
19
7
Operating Income
-27
-13
-26
0
0
-35
-53
-54
-38
-66
EBITDA
-24
-10
-14
0
46
-37
-68
-47
-32
-54
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
1
3
3
3
3
3
3
3
3
2
Income Before Tax
-26
-1
-17
-2
43
-40
-71
-50
-35
-57
Income Tax Expense
0
1
0
6
-1
0
-1
0
0
0
Net Income
-28
-3
-19
-9
46
-43
-70
-50
-35
-57
Net Profit Margin
-164.24%
-10.09%
-96.09%
-16.95%
79.75%
-214.48%
-1485.07%
-974.46%
-180.65%
-759.51%

Immatics N.V. Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
4
20
38
39
182
58
163
48
Gross Profit
-34
-24
-43
-59
69
-70
163
48
Operating Income
-34
-33
-69
-86
29
-101
-38
-182
EBITDA
-31
-28
-207
-87
50
-88
34
-185
Interest Expense
0
0
0
0
1
0
0
0
Depreciation
2
3
4
5
6
7
12
12
Income Before Tax
-32
-32
-229
-93
42
-96
21
-198
Income Tax Expense
-2
0
0
1
4
-2
6
-1
Net Income
-35
-35
-278
-107
39
-105
15
-196
Net Profit Margin
-834.06%
-172.05%
-733.84%
-273.45%
21.71%
-179.63%
9.77%
-407.01%

Immatics N.V. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-3
-18
-8
44
-39
-70
-52
-35
-58
Operating Cash Flow
-32
-33
-33
-58
-34
-39
-44
-57
-42
Investing Cash Flow
-241
69
67
-47
46
64
122
-29
-28
Financing Cash Flow
174
0
0
146
0
0
0
98
21
Change in Cash
-96
36
31
47
6
13
78
10
-51

Immatics N.V. Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-32
-229
-93
37
-94
15
-188
Operating Cash Flow
70
-85
-81
100
18
-158
-169
Investing Cash Flow
-5
-15
7
-209
-31
-152
196
Financing Cash Flow
-1
207
-2
123
84
319
93
Change in Cash
63
104
-74
15
69
18
137

Global Institutional Holdings in Immatics N.V.

Funds
Holdings
RTW INVESTMENTS, LLC
9.42%
Sofinnova Ventures
2.66%
Aberdeen Group PLC
0.6%
Lynx1 Capital Management, LP
0.69%
Woodline Partners LP
0.73%
See all

Insights on Immatics N.V.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, IMTX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, IMTX stock has moved up by 4.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Immatics N.V. Ordinary Shares has experienced a drawdown of -23.1%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 1.0%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -35.69M → -57.81M (in $), with an average decrease of 62.0% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 19.76M → 7.61M (in $), with an average decrease of 61.5% per quarter

About Immatics N.V.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
OrganisationImmatics N.V.
HeadquartersPaul-Ehrlich-Strasse 15-19, Tübingen, Germany, 72076
IndustryBiotechnology
CEODr. Harpreet Singh Ph.D.
E-voting on sharesClick here to vote

Key Management of Immatics N.V.

Name

Title

Dr. Carsten Reinhardt M.D., Ph.D.

Chief Development Officer

Ms. Amie Krause

Chief People Officer

Dr. Hans-Georg Rammensee Ph.D.

Co-Founder & Member of the Scientific Advisory Board

Ms. Lauren Schroeder

Vice President of Marketing

Mr. Steffen Walter Ph.D.

Chief Operations Officer

Mr. Ephraim Hofsäß M.Sc.

Vice President of SEC Reporting & Accounting

Mr. Edward A. Sturchio

General Counsel & Secretary

Dr. Harpreet Singh Ph.D.

CEO, MD, Member of Management Board & Executive Director

Dr. Venkat Ramanan Ph.D.

Chief Financial Officer

Dr. Toni Weinschenk Ph.D.

Co-Founder & Chief Innovation Officer

FAQs

What is Immatics N.V. share price today?

Immatics N.V. share price today is $9.78 as on at the close of the market. Immatics N.V. share today touched a day high of $9.98 and a low of $9.62.

What is the 52 week high and 52 week low for Immatics N.V. share?

Immatics N.V. share touched a 52 week high of $12.41 on and a 52 week low of $5.05 on . Immatics N.V. stock price today i.e. is closed at $9.78,which is 21.19% down from its 52 week high and 93.66% up from its 52 week low.

What is Immatics N.V.'s market capitalisation today?

Immatics N.V. market capitalisation is $0.00T as on .

How to invest in Immatics N.V. Stock (IMTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Immatics N.V. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Immatics N.V. Shares that will get you 0.1534 shares as per Immatics N.V. share price of $9.78 per share as on June 19, 2026 at 8:45 am IST.

What is the minimum amount required to buy Immatics N.V. Stock (IMTX) from India?

Indian investors can start investing in Immatics N.V. (IMTX) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Immatics N.V. stock (as per the Rupee-Dollar exchange rate as on ). Based on Immatics N.V. share’s latest price of $9.78 as on June 19, 2026 at 8:45 am IST, you will get 1.0225 shares of Immatics N.V.. Learn more about fractional shares .

What are the returns that Immatics N.V. has given to Indian investors in the last 5 years?

Immatics N.V. stock has given -17.12% share price returns and 27.56% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?